Welcome to our dedicated page for Bausch + Lomb Corporation news (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb Corporation stock.
Bausch + Lomb Corporation (NYSE/TSX: BLCO) is a global eye health company that regularly issues news on its business segments, financing activities, partnerships and product pipeline. As an ophthalmic goods manufacturer with operations in vision care, surgical products and ophthalmic pharmaceuticals, the company’s announcements cover a broad range of topics relevant to investors and those following the eye health sector.
News updates include financial results, such as quarterly revenue performance across the Vision Care, Surgical and Pharmaceuticals segments, as well as details on operating income, adjusted metrics and guidance ranges. The company also uses press releases to outline strategic plans and multi-year financial targets, describe its product pipeline in areas like dry eye, glaucoma, ocular surface pain and age-related macular degeneration, and highlight clinical-stage programs and anticipated launches across consumer, pharmaceutical, surgical and contact lens businesses.
Bausch + Lomb’s news flow also features information on capital structure and liquidity, including amendments to its credit agreement, new term loan tranches, revolving credit facilities and senior secured notes offerings, along with the intended use of proceeds for refinancing existing debt. Governance and leadership developments, such as board appointments, committee assignments and changes related to director nomination agreements, are disclosed through current reports and accompanying press releases.
In addition, the company issues news about partnerships and initiatives in eye health, including collaborations with organizations focused on glaucoma research and awareness, and sustainability programs like the ONE by ONE Recycling Program and the Every Contact Counts program. For readers tracking BLCO, this news page aggregates these updates so they can review company communications on financial performance, strategic direction, product development, governance and eye health initiatives in one place.
Bausch + Lomb (NYSE/TSX: BLCO) announced that CEO Joseph C. Papa will speak at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. ET. A live webcast will be accessible on the company's Investor Relations page. Bausch + Lomb is a prominent global eye health company founded in 1853, focusing on a diverse portfolio of over 400 products, including contact lenses and surgical instruments, with operations in nearly 100 countries.
Summary not available.
Bausch + Lomb Corporation and Bausch Health Companies announced the closing of Bausch + Lomb's IPO, selling 35 million shares at $18.00 each, generating $630 million. Bausch Health retains approximately 90% of Bausch + Lomb's shares. The IPO proceeds and new loans will be used to repay existing debts, including Bausch Health’s 6.125% Notes due 2025. Bausch Health also canceled the redemption of its 9.000% Senior Notes due 2025. The IPO began trading under the ticker symbol BLCO on May 6, 2022.
Bausch + Lomb has officially launched trading under the ticker BLCO on the NYSE and TSX as of May 6, 2022. This marks a significant step towards its goal of being an independent company focused on eye health. With over 400 products, including renowned brands like Biotrue and VYZULTA, Bausch + Lomb aims to enhance vision for millions worldwide. The management team, led by CEO Joseph C. Papa, includes experienced professionals from the healthcare sector. The company is committed to innovation and sustainable practices, emphasizing its mission to improve eye health globally.
Bausch + Lomb Corporation, a subsidiary of Bausch Health (NYSE/TSX: BHC), has announced the pricing of its initial public offering (IPO) of 35 million common shares at $18.00 each. Bausch + Lomb will not receive the proceeds from this offering, as it is being conducted by the Selling Shareholder. The shares are set to trade on the NYSE and TSX under the ticker symbol 'BLCO' starting May 6, 2022. Following the IPO, Bausch Health will retain around 90% of Bausch + Lomb's shares, decreasing to 88.5% if the underwriters' over-allotment option is fully exercised.